|
Cancer | Males | Males | Females | Females | RR and 95% CI | Population-attributable risk Percent | RR and 95% CI | Population-attributable risk Percent |
| Colon | 1.57 (1.48, 1.65)* | 11.5% (9.9, 13.1)* | 1.19 (1.04, 1.36)* | 4.2% (0.9, 7.7) | Endometrial | NA | NA | 1.85 (1.3, 2.65)* | 16.5% (6.5, 27.7)* | Esophageal | 1.23 (0.58, 2.60) | — | 2.04 (1.18, 3.55)* | 19.4% (4.0, 37.2)* | Gallbladder | 1.47 (1.17, 1.85)* | 9.7% (3.7, 16.3)* | 1.82 (1.32, 2.50)* | 16% (6.9, 25.8)* | Leukemia | 1.16 (0.88, 1.52) | — | 1.32 (1.08, 1.60)* | 6.9% (1.8, 12.2)* | Malignant melanoma | 1.26 (1.07, 1.48)* | 5.6% (1.6, 9.9)* | 0.95 (0.84, 1.07) | — | Multiple myeloma | 0.58 (0.36, 0.93)* | — | 1.20 (0.99, 1.45) | — | Non-Hodgkin lymphoma | 1.09 (0.98, 1.21) | — | 0.91 (0.86, 0.97)* | | Pancreatic | 1.36 (1.07, 1.73)* | 7.6% (1.6, 17.5)* | 1.34 (1.22, 1.46)* | 7.3% (4.9, 9.6)* | Postmenopausal breast | NA | NA | 1.25 (1.07, 1.46)* | 5.5% (1.6, 9.6)* | Rectal | 1.22 (0.91, 1.64) | — | 1.03 (0.74, 1.44) | — | Renal | 1.57 (1.38, 1.77)* | 11.5% (8.0, 15.0)* | 1.72 (1.58, 1.88)* | 14.3% (12.0, 16.9)* | Thyroid | 1.12 (0.72, 172) | — | 1.03 (0.87, 1.23) | — |
|
|